LC
RDY icon

Lindbrook Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

Lindbrook Capital’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$214K Sell
16,242
-5,379
-25% -$74.2K 0.02% 399
2024
Q4 		$341K Buy
21,621
+2,311
+12% +$34.7K 0.03% 287
2024
Q3 		$307K Sell
19,310
-1,235
-6% -$19.9K 0.03% 304
2024
Q2 		$313K Buy
20,545
+1,180
+6% +$16.9K 0.03% 278
2024
Q1 		$284K Buy
19,365
+1,770
+10% +$25.8K 0.03% 295
2023
Q4 		$245K Buy
17,595
+2,825
+19% +$37.8K 0.02% 308
2023
Q3 		$198K Buy
14,770
+440
+3% +$5.95K 0.02% 317
2023
Q2 		$181K Sell
14,330
-875
-6% -$10.2K 0.02% 350
2023
Q1 		$173K Buy
15,205
+1,250
+9% +$13.5K 0.02% 347
2022
Q4 		$144K Buy
13,955
+2,415
+21% +$26.1K 0.02% 402
2022
Q3 		$121K Sell
11,540
-160
-1% -$1.7K 0.02% 394
2022
Q2 		$130K Buy
11,700
+1,720
+17% +$18.7K 0.02% 389
2022
Q1 		$111K Buy
9,980
+2,450
+33% +$27.8K 0.02% 433
2021
Q4 		$99K Buy
7,530
+880
+13% +$11.1K 0.02% 497
2021
Q3 		$87K Sell
6,650
-220
-3% -$2.93K 0.02% 296
2021
Q2 		$101K Buy
6,870
+155
+2% +$2.17K 0.02% 295
2021
Q1 		$82K Buy
6,715
+285
+4% +$3.66K 0.02% 315
2020
Q4 		$92K Buy
6,430
+60
+0.9% +$808 0.02% 261
2020
Q3 		$89K Sell
6,370
-1,815
-22% -$21.6K 0.02% 232
2020
Q2 		$87K Buy
8,185
+280
+4% +$2.85K 0.03% 237
2020
Q1 		$64K Sell
7,905
-130
-2% -$1.08K 0.02% 267
2019
Q4 		$65K Buy
8,035
+255
+3% +$2.01K 0.02% 361
2019
Q3 		$59K Buy
7,780
+545
+8% +$4.05K 0.02% 365
2019
Q2 		$54K Buy
7,235
+355
+5% +$2.79K 0.02% 398
2019
Q1 		$55K Buy
6,880
+420
+7% +$3.19K 0.02% 372
2018
Q4 		$48K Buy
+6,460
New +$45.4K 0.02% 355

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lindbrook Capital's RDY Position: Q1 2025 in Review

Lindbrook Capital reduced its Dr. Reddy's Laboratories (RDY) stake by 25% in Q1 2025, selling an estimated $74.2K and leaving 16,242 shares worth $214K. The position accounts for 0.02% of the portfolio, ranked #399.

Lindbrook Capital first reported a position in RDY in Q4 2018 and has held it in 26 quarters since. The position peaked at $341K in Q4 2024. 244 funds tracked by Wall St. Rank hold RDY as of Q1 2025.

  • Lindbrook Capital held 16,242 shares of Dr. Reddy's Laboratories worth $214K as of Q1 2025.
  • Lindbrook Capital sold 5,379 Dr. Reddy's Laboratories shares in Q1 2025, an estimated $74.2K.
  • Dr. Reddy's Laboratories made up 0.02% of Lindbrook Capital's portfolio in Q1 2025, its #399 holding.
  • Lindbrook Capital first reported a position in Dr. Reddy's Laboratories in Q4 2018 and has held it in 26 quarters since.
  • Lindbrook Capital's Dr. Reddy's Laboratories position peaked at $341K in Q4 2024.
  • 244 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.